A recent hallmark study, the Empagliflozin Outcome Trial in Patients with Chronic HFpEF (EMPEROR-Preserved), showed that empagliflozin reduced the risk of cardiovascular death or hospitalization for HF in both diabetic and non-diabetic patients with HFpEF.350 Significantly, this makes SGLT2 inhibitors the first class of medications to confer benefits across both HFrEF and HFpEF, and a promising therapy for treating diabetic cardiomyopathy. Here, SLC5A2 is linked to diabetic cardiomyopathy.